Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity

Clinical and Experimental Immunology - Tập 170 Số 2 - Trang 167-177 - 2012
Shengqian Hong1, H Li1, Jianfei Qian1, Jian Yang1, Yong Lu1, Qing Yi1
1Department of Lymphoma/Myeloma, Division of Cancer Medicine, and Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Tóm tắt

SummaryDendritic cells (DCs) are the most potent antigen-presenting cells and are the mediators of T cell immunity. Many investigators have explored the potential of using DCs as a vaccine for tumour-derived antigens in immunotherapy of B cell malignancies, and the results have been disappointing. To search for better tumour antigens to improve the efficacy of DC-based immunotherapy in myeloma, we evaluated and compared the efficacy of the vaccination of DCs pulsed with idiotype (Id) or tumour lysate in the 5TGM1 myeloma mouse model. Our results showed that Id- or tumour lysate-pulsed DC vaccines protected mice efficiently against developing myeloma, retarded tumour growth, induced tumour regression against established tumour and protected surviving mice from tumour rechallenge. The therapeutic responses were associated with an induction of strong humoral immune responses, including anti-Id or anti-lysate antibodies, and cellular immune responses including myeloma-specific CD8+ cytotoxic T lymphocytes, CD4+ type 1 T helper cells and memory T cells in mice receiving Id- or tumour lysate-pulsed DC vaccines. In addition, our studies showed that tumour lysate-pulsed DCs were more potent vaccines than the Id-pulsed DC vaccines to promote anti-tumour immunity in the model. This information will be important for improving the strategies of DC-based immunotherapy for patients with myeloma and other B cell tumours.

Từ khóa


Tài liệu tham khảo

Palumbo, 2011, Multiple myeloma, N Engl J Med, 364, 1046, 10.1056/NEJMra1011442

Kyle, 2008, Multiple myeloma, Blood, 111, 2962, 10.1182/blood-2007-10-078022

Yi, 2003, Immunotherapy in multiple myeloma: current strategies and future prospects, Exp Rev Vaccines, 2, 391, 10.1586/14760584.2.3.391

Rosenberg, 2004, Cancer immunotherapy: moving beyond current vaccines, Nat Med, 10, 909, 10.1038/nm1100

Yi, 2009, Novel immunotherapies, Cancer J, 15, 502, 10.1097/PPO.0b013e3181c51f0d

Banchereau, 1998, Dendritic cells and the control of immunity, Nature, 392, 245, 10.1038/32588

Young, 1996, Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity, J Exp Med, 183, 7, 10.1084/jem.183.1.7

Grabbe, 1995, Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?, Immunol Today, 16, 117, 10.1016/0167-5699(95)80125-1

Girolomoni, 1997, Dendritic cells hold promise for immunotherapy, Immunol Today, 18, 102, 10.1016/S0167-5699(97)01030-X

Steinman, 2001, Active immunization against cancer with dendritic cells: the near future, Int J Cancer, 94, 459, 10.1002/ijc.1503

Wen, 2001, Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells, Blood, 97, 1750, 10.1182/blood.V97.6.1750

Hong, 2008, Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth, Cancer Res, 68, 8456, 10.1158/0008-5472.CAN-08-2213

Titzer, 2000, Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects, Br J Haematol, 108, 805, 10.1046/j.1365-2141.2000.01958.x

Yi, 2002, Optimizing dendritic cell-based immunotherapy in multiple myeloma, Br J Haematol, 117, 297, 10.1046/j.1365-2141.2002.03411.x

Curti, 2007, Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides, Br J Haematol, 139, 415, 10.1111/j.1365-2141.2007.06832.x

Yi, 2010, Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients, Br J Haematol, 150, 554, 10.1111/j.1365-2141.2010.08286.x

Wen, 2002, Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy, Blood, 99, 3280, 10.1182/blood.V99.9.3280

Raje, 2004, Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma, Br J Haematol, 125, 343, 10.1111/j.1365-2141.2004.04929.x

Hao, 2004, Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells, Exp Oncol, 26, 300

Walewska, 2007, Preclinical development of hybrid cell vaccines for multiple myeloma, Eur J Haematol, 78, 11, 10.1111/j.1600-0609.2006.00769.x

Garrett, 1997, A murine model of human myeloma bone disease, Bone, 20, 515, 10.1016/S8756-3282(97)00056-2

Mundy, 2001, Preclinical models of bone metastases, Semin Oncol, 28, 2, 10.1016/S0093-7754(01)90225-8

Liso, 2000, Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma, Biol Blood Marrow Transplant, 6, 621, 10.1016/S1083-8791(00)70027-9

Kwak, 1996, Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response, Proc Natl Acad Sci USA, 93, 10972, 10.1073/pnas.93.20.10972

Lutz, 1999, An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow, J Immunol Methods, 223, 77, 10.1016/S0022-1759(98)00204-X

Qian, 2005, Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96, Clin Cancer Res, 11, 8808, 10.1158/1078-0432.CCR-05-1553

Wang, 2007, Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma, Front Biosci, 12, 3566, 10.2741/2335

Qian, 2007, Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma, Blood, 110, 1587, 10.1182/blood-2007-03-082529

Houot, 2009, Vaccines for lymphomas: idiotype vaccines and beyond, Blood Rev, 23, 137, 10.1016/j.blre.2008.09.001

Boon, 1994, Tumor antigens recognized by T lymphocytes, Annu Rev Immunol, 12, 337, 10.1146/annurev.iy.12.040194.002005

Nestle, 1998, Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells, Nat Med, 4, 328, 10.1038/nm0398-328

Maier, 2003, Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells, Blood, 102, 2338, 10.1182/blood-2002-08-2455

Holtl, 2002, Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells, Clin Cancer Res, 8, 3369

Hus, 2005, Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia, Leukemia, 19, 1621, 10.1038/sj.leu.2403860

Asosingh, 2000, The 5TMM series: a useful in vivo mouse model of human multiple myeloma, Hematol J, 1, 351, 10.1038/sj.thj.6200052

Radl, 1979, Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice, J Immunol, 122, 609, 10.4049/jimmunol.122.2.609

Bogen, 2000, Deletion of idiotype (Id)-specific T cells in multiple myeloma, Acta Oncol, 39, 783, 10.1080/028418600750063505

Thông tin
Thông tin xuất bản

Clinical and Experimental Immunology

Tập 170 Số 2

167-177

Thông tin tác giả